The most impactful innovations don’t disrupt what already works—they build on it, refining and amplifying the strengths of existing systems. In the latest Collaborate Forward InterVIEW, leaders from Science 37 explore how decentralized and site-based clinical trial approaches can complement each other. Don’t miss this important conversation about the synergy between innovation and tradition in clinical research. Read more: https://bit.ly/4uZ7HIo

What if your next technology role could have an impact beyond the screen? In our latest article, colleagues from Syneos Technology Solutions share their perspectives on product innovation, global collaboration, and supporting the future of clinical research. 📖 Read the article: https://lnkd.in/gqUxf5JA

Outside-In #3 What Happens When We Game Statistics Instead of Doing Science (Part 1 & Part 2) Part 2: Returning to Needs & Science — Decision Reset Behind Industrial Differentiation Continuing the reflection raised in Part 1, the FDA’s rigorous stance on statistical manipulation draws a clear bottom line for global healthcare innovation: statistical significance should only be the result of rigorous scientific research, never a pre-designed target to be artificially achieved. Genuine biomedical innovation follows an irreversible, logical sequence: identify unmet clinical needs first, drive research based on fundamental scientific advances, lock statistical protocols before trial initiation, and validate value through objective outcomes. There is no reverse engineering of conclusions. Against this benchmark, the biotech industry is undergoing definitive structural differentiation. Global capital has completely abandoned concept-driven storytelling and homogeneous copycat R&D. Resources are now concentrating exclusively on enterprises with tangible, long-term competitive moats: those with iterative proprietary technology platforms, pipelines delivering verifiable clinical benefits, and proven capabilities for global clinical layout and cross-border commercialization. Fast-follow strategies can support short-term technical accumulation, yet they cannot sustain long-term industrial competitiveness. As regulation tightens, capital allocation becomes rationalized, and clinical evaluation grows refined, data-driven cosmetic innovation and blind target crowding are being continuously eliminated from the market. At this critical turning point, profound introspection is necessary for all R&D leaders, investors, and board members shaping industrial decisions. We must reflect on the essence of our R&D motives: whether our pipeline iteration truly resolves unmet patient needs, or merely generates data catering to financing and regulatory expectations. We need to reconsider the rationality of continuous investment in overcrowded tracks that lack foundational scientific differentiation. Most importantly, we must evaluate whether the so-called R&D advantages built on imitation and data optimization constitute sustainable technological barriers, or merely fragile paper prosperity adapted for short-term capital cycles. The underlying logic of innovation remains eternally consistent: true innovation solves real problems, not beautiful numbers. For the entire healthcare innovation ecosystem, this is the ultimate principle that guides long-term value creation. #OutsideIn #ChinaBiotech #FirstInClass #BiotechInvestment #IndustrialDifferentiation #ScienceDrivenInnovation

At BiomimX, this is not just a philosophy but it's how we operate every day. Our Co-Founder & CEO Paola Occhetta has always believed that rigorous, well-validated science is the strongest foundation you can build a company on. But as she said, bringing truly innovative tools to the market requires more than great technology, it requires changing mindsets, building regulatory pathways, and fostering collaboration across the whole industry. A message worth amplifying! 📣

Investing in Health Means Investing in Humanity Medical investing is not only about identifying the next promising technology. It is about recognizing which ideas can solve real problems, improve patient outcomes, and create lasting value for society. The strongest opportunities are rarely the loudest ones. They often require patience, careful judgment, and the conviction to support meaningful innovation before the results become obvious. Capital can accelerate progress—but vision determines where that capital creates the greatest impact. When evaluating healthcare innovation, what matters most to you: scientific potential, patient impact, or long-term scalability?

The Relay Continues: Building Biotechs That Save Lives | How America Makes Medicine Ep. 3 Every breakthrough medicine begins with a scientific discovery. But turning that discovery into a treatment that reaches patients requires navigating one of the most challenging journeys in medicine. https://lnkd.in/ehnx8Thk

🧬 Scientific breakthroughs don't change healthcare. Adoption does. The UK has no shortage of world-class science, innovative founders and pioneering research. Yet the biggest challenge for many science-led companies isn't developing a breakthrough, it's successfully scaling it. In our latest blog, drawing on lessons from Oxford Nanopore Technologies' journey and insights from Green Templeton College, University of Oxford, we explore what it really takes to scale a science-led company. From the role of location and innovation ecosystems, to the challenge of driving adoption, our blog examines how businesses can bridge the gap between scientific excellence and commercial success. As healthcare systems face growing pressures, helping innovation reach patients faster has never been more important. 📖 Read Gayle Curry's blog 👉 https://lnkd.in/epcZuCmR #HealthcareInnovation #HealthTech #LifeSciences #MedTech #Commercialisation #InnovationLeadership #ScaleUp Robert Pinheiro I Dr Pete Jordan I Christiaan de Koning, PhD

The Oxford Health Innovation Forum is a university-wide initiative being piloted at Green Templeton in 2026.  Gayle Curry considers the output from a recent series of lectures that @null have sponsored - this blog covers what it really takes to scale a science-led company #HealthTech #HealthcareInnovation #MedTech

The biggest healthcare challenges cannot be solved by one field alone. Biology, nutrition, technology, medicine, and data science are becoming increasingly connected. The most valuable innovations often happen when different perspectives meet. A scientist may see a biological problem. An engineer may see a technology solution. An entrepreneur may see a market opportunity. Together, they can create something bigger. Collaboration is becoming one of the most important drivers of progress. #Collaboration #Innovation #Biotechnology

Discovering the power of a plant took months of dedicated research, exploring scientific literature, and engaging with experts. The journey revealed a valuable resource that, surprisingly, remains largely unknown and poorly marketed. It's often found in basic packaging, lacking proper guidance for use. This raises a critical question: why is such a beneficial plant so inaccessible and misunderstood by the public? #BotanicalResearch #ScientificDiscovery #PlantScience #Innovation #MarketGaps